TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Microbiome in Colorectal Cancer Onset and Progression

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 50-80~* with a signed Informed Consent Form~* able to comply with the protocol requirements AND~* Confirmed primary diagnosis of colorectal cancer (stage I (1), II (2) and III (3)), or pre-- cancerous polyps, including tubulovillous or villous adenomas, with a biopsy available for study assays OR~* CRC-free and polyp-free colon using colonoscopy~Exclusion Criteria:~* Diagnosis of CRC relapse at the time of enrollment~* Inflammatory bowel disease~* Irritable bowel syndrome (IBS), confirmed at enrollment~* Pregnant, planning to become pregnant during the study timeline or nursing~* Cholecystectomy (gallbladder removal)~* Bariatric/gastric surgery~* Partial colectomy (colon removal)~* Partial bowel resection~* Pancreatic surgery~* Lynch syndrome~* Familial polyposis~* Patients from which the healthcare providers do not collect biopsy at colonoscopy AND undergo neoadjuvant therapy prior to surgery (the microbial composition of the biopsy at the time of surgery may be significantly affected by neoadjuvant therapy).~* Known autoimmune condition or impairment of immunological functions (e.g. HIV infection)~* Medications: Receipt of biologics, systemic immunosuppressive therapy, incl. cancer therapy, or antibiotics in the last 3 months before initial diagnosis~* Any vaccine taken within the last 30 days~* Current receipt of investigational agent

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Cancer-free (Type: None): Have confirmed colorectal cancer-free and Polyp-free colon using colonoscopy
- Pre-cancerous (Type: None): Have benign or precancerous polyps, including tubulovillous or villous adenomas, using colonoscopy
- Colorectal cancer stage I (Type: None): Have confirmed TNM staging of colorectal cancer~The T refers to the size and extent of the main tumor. The main tumor is usually called the primary tumor.~The N refers to the number of nearby lymph nodes that have cancer. The M refers to whether the cancer has metastasized. This means that the cancer has spread from the primary tumor to other parts of the body.
- Colorectal cancer stage II (Type: None): Have confirmed TNM staging of colorectal cancer~The T refers to the size and extent of the main tumor. The main tumor is usually called the primary tumor.~The N refers to the number of nearby lymph nodes that have cancer. The M refers to whether the cancer has metastasized. This means that the cancer has spread from the primary tumor to other parts of the body.
- Colorectal cancer stage III (Type: None): Have confirmed TNM staging of colorectal cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants who were randomized into Study SHP607-202 (NCT03253263). Participants who were randomized, but did not complete Study SHP607-202 (NCT03253263) must be at least 12 months CA.~* Written informed consents (and assents, if applicable) must be signed and dated by the participant's parent(s)/legally authorized representative(s) prior to any study-related procedures. The informed consent and any assents for underage parents must be approved by the institutional review board (IRB)/independent ethics committee (IEC).~Exclusion Criteria:~- Participants are excluded from the study if the participant or participant's parent(s)/legally authorized representative(s) is/are unable to comply with the protocol or is/are unlikely to be available for long-term follow-up as determined by the investigator.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 24 Months
- Healthy Volunteers: f

Study Arms:
- SHP607 250 mcg/kg/24 hours (Type: None): Participants who received 250 micrograms per kilogram per 24 hours (mcg/kg/24 hours) in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
- SHP607 400 mcg/kg/24 hours (Type: None): Participants who received 400 mcg/kg/24 hours in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
- Standard Neonatal Care (Type: None): Participants who received standard neonatal care in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Sleep Disordered Breathing in Precapillary Pulmonary Hypertension: Effect of CPAP Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* minimum 18 years old~* diagnosed with PAH or non-operable CTEPH or operated CTEPH with peristent pulmonary hypertension~* diagnosis of PAH based on cardiac catherisation~* diagnosis of CTEPH confirmed by contrast-enhanced spiral chest CT, pulmonary angiography and V/Q scintigraphy~* recent diagnosis of sleep disordered breathing (polysomnography realized within 3 months before inclusion showing AHI above 15) stable clinical condition for at least 3 months before inclusion as defined by NYHA and a walking distance difference within 10% of the previous 3 months and no change in medical therapy during this 3 months~Exclusion Criteria:~* congenital heart disease~* moderate and severe restrictive or obstructive pulmonary disease with a TLC and a FEV1\<60% of the predicted value~* BMI 35kg/m2 or more~* patients already treated with CPAP~* patients with severe sleepiness (epworth sleepiness scale from 18 to 24/24)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cpap treatment (Type: OTHER): patients randomized to the 'no cpap' arm will not be treated by CPAP
- no cpap (Type: NO_INTERVENTION): patients randomized to the 'cpap' arm will be treated by CPAP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of rheumatoid arthritis ≥6 months duration and American College of Rheumatology (ACR) Class I-III functional status at screening and baseline visits;~* Active disease defined as:~  * At least 6 of 68 tender joints and 6 of 66 swollen joints at screening and baseline visits, and~ * hs-C-Reactive Protein (hs-CRP) \>10 g/L or Erythrocyte Sedimentation Rate (ESR) \>28 mm/hr at screening visit;~* Continuous treatment with Methotrexate for at least 12 weeks and on stable dose (minimum 10 mg/week) for at least 6 weeks prior to the screening visit;~* Participant considered as Primary TNF-α blocker nonresponder. i.e.:~  * Appropriate for previous TNF-α blocker therapy~ * Lack of adequate clinical response after at least 3 months TNF-α blocker therapy with MTX or other synthetic disease modifying anti-rheumatic drug (DMARD) co-therapy.~Exclusion criteria:~* Age \<18 years or \>75 years;~* Pregnant or breastfeeding woman or woman of childbearing potential, unwilling to utilize adequate contraception or not to become pregnant during the entire study;~* Fever (\>38°C), or chronic, persistent, or recurring infection(s);~* History of demyelinating disease;~* Current underlying hepatobiliary disease.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 2 mL to match sarilumab once a week (qw) and 0.5 mL to match golimumab every 4 weeks (q4w) on top of MTX (15-25 mg) qw for 12 weeks.
- Golimumab 50 mg (Type: ACTIVE_COMPARATOR): Golimumab 50 mg q4w and placebo (matched to sarilumab) qw on top of MTX (15-25 mg) qw for 12 weeks.
- Sarilumab 150 mg (Type: EXPERIMENTAL): Sarilumab 150 mg qw and placebo (matched to golimumab) q4w on top of MTX (15-25 mg) qw for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age \& histologic diagnosis of adenocarcinoma of the prostate~* Completed surgery or radiation at least 8 weeks prior to entry with removal of all visible disease~* Clinical Stage D0 prostate cancer with rising PSA and PSA \>2ng/ml.~* ECOG performance of \<2~* Normal hematologic, renal and liver function~Exclusion Criteria:~* Cannot have evidence of immunosuppression or have been treated with immunosuppressive therapy.~* No prior treatment with an LHRH agonist or nonsteroidal antiandrogen such as casodex or flutamide~* No evidence for metastatic disease per bone scan or CT scan of the abdomen and pelvis~* No prior treatment with anti-CTLA 4 monoclonal antibody~* No history of known autoimmune disorder or HIV, hepatitis B or hepatitis C~* No known brain metastases~* No history of inflammatory bowel conditions including diverticulitis, ulcerative colitis, etc.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bicalutamide 150mg orally days 1-28 followed by CP-675,206 IV on day 29. Cycle is repeated once at month 3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Improving Labour Induction Analgesia: Epidural Fentanyl Bolus at Epidural Initiation for Induction of Labour

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy parturients~* Parturients presenting for labour induction for post-term pregnancy (i.e. pregnancy beyond 42 weeks gestational age)~* Parturients who have had an uncomplicated pregnancy~Exclusion Criteria:~* Parturients presenting for induction of labour for pre-labour (premature) rupture of membranes~* Parturients presenting for induction of labour for hypertensive disorders of pregnancy \[including preeclampsia, eclampsia, HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets)\]~* Parturients with maternal diabetes~* Fetal growth restriction~* Multiple gestation pregnancy~* Known or suspected Chorioamnionitis~* Known or suspected Abruptio placentae~* Oligohydramnios~* Parturients with cholestasis of pregnancy~* Known alloimmunization with fetal effects.~* Parturients with other chronic medical conditions or any complications related to pregnancy~* Participants who lack capacity to consent on their own behalf

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Control Group (No Additional Epidural Fentanyl Bolus) (Type: ACTIVE_COMPARATOR): The Control group will receive a 2 ml bolus of standard epidural mix solution after epidural placement followed by standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia.
- Fentanyl bolus group (Type: EXPERIMENTAL): The Fentanyl bolus group will receive a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent,~* Age \> 18,~* Ejection fraction ≥ 50%,~* hospitalization for heart failure in the last 6 months and~* current NYHA Class II-IV symptoms, OR~* current NYHA Class III-IV symptoms and one of the following:~  1. ECG or echocardiographic evidence of moderate/severe left ventricular hypertrophy,~ 2. chest x-ray evidence of pulmonary congestion~Exclusion Criteria:~* Probable alternative cause of symptoms (pulmonary disease, severe anemia, etc.)~* Prior documented LVEF \< 40% or qualitative moderate or greater LV systolic dysfunction.~* Current indication for statin therapy~* Intolerance to statin therapy.~* Documented ischemic heart disease requiring lipid-lowering therapy (i.e. CAD, myocardial infarction, stroke)~* Evidence of significant myocardial ischemia on stress testing at screening visit.~* Evidence of hepatic abnormality (defined as liver enzymes \> 2 times the upper limit of normal values).~* Uncontrolled hypertension (BP \> 150/100)~* Significant valvular disease.~* Atrial fibrillation~* Known familial hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy.~* Restrictive cardiomyopathy or systemic illness known to be associated with infiltrative heart disease (i.e. amyloidosis, sarcoidosis, hemochromatosis).~* Cor pulmonale or other cause of right heart failure not related to LV dysfunction.~* Clinically significant pulmonary disease.~* Pericardial constriction or hemodynamically significant pleural effusion.~* Uncontrolled arrhythmia.~* Any systemic condition other than heart failure that may limit survival to less than 2 years.~* Advance renal disease (serum creatinine \> 3.0 mg/dl or on dialysis)~* Known intolerance or allergy to HMG CoA reductase inhibitors~* Uncontrolled hyper- or hypothyroidism.~* Any subject characteristic that may interfere with study compliance, such as baseline dementia, substance abuse, history of non-compliance with medications or appointments.~* Prisoners or other vulnerable populations.~* Any woman of child-bearing age with a documented positive pregnancy test.~* Subject is receiving therapy with other investigational therapy or is participating in any other clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): Heart failure patients assigned to atorvastatin
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Think AHEAD (A Healthy Eating And Drinking) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI ≥ 85th percentile for sex and age according to CDC growth charts~* Access to a working telephone and cell phone~* At least one parent willing and able to participate in the intervention with the subject~* Residing in predominately one household (no more than one weekend every two weeks in a secondary household)~* Medical clearance from a primary care provider or treating physician to rule out any major medical illness, disability, or disorder (e.g., liver disease, renal failure, cancer)~Exclusion Criteria:~* Intake of more than 4 cups (250 mL per cup) of water per day~* BMI ≥ 40 kg/m2~* Currently smoking (\> 1 cigarette in the past week)~* Major surgery within the previous 6 months~* Does not have a primary care provider~* Physician diagnosis of a major medical illness (e.g. diabetes)~* Previous diagnosis of an eating disorder~* Physical, mental, or cognitive handicaps that prevent participation~* Chronic use of medications that may affect study outcomes (e.g. stimulants or diuretics)~* Another member of the family (first degree relative) or household participating in the study~* A friend, classmate or coworker participating in the study with whom they have contact with one or more times per week~* Girls who are pregnant, planning to become pregnant in the next 6 months, lactating, or within 6 months postpartum

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Diet + Water (Type: EXPERIMENTAL): Participants will be counseled to follow a standard weight-reducing diet including consumption of 1) ample vegetables, fruits, and legumes; 2) whole rather than refined grains; and 3) high-quality proteins at most meals and snacks. Moreover, we will recommend limiting intake of added fats and sugars and avoiding juices and sugar-sweetened beverages (per standard practice). Participants will also be counseled to increase their water intake to 8 cups per day, consistent with the popular 8 × 8 recommendation (eight 8-oz glasses of water).
- Diet (Type: ACTIVE_COMPARATOR): Participants will be counseled on the same standard weight-reducing diet, as described above, with no specific advice regarding water consumption. Furthermore, no specific dietary recommendations will be provided on altering fluid/beverage intake, other than to decrease calorie-containing beverages as noted above. When participants ask for a recommendation regarding water intake, they will be advised that drinking plain water is the best way to satisfy thirst and instructed to drink when thirsty.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Discharge Counseling and Medication Therapy Management (MTM) Services After Discharge for Heart Failure Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Heart Failure with high risk for readmission.~* Enroll in study prior to hospital discharge.~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Discharge counseling and MTM follow-up (Type: EXPERIMENTAL): At the time of hospital discharge the subject will receive:~* Discharge medication counseling from a pharmacist~* Home medication if needed~* Approximately 7 days after hospital discharge the subject have a Follow-up visit at Medication Therapy Management clinic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 50 years of age or older diagnosed in the study eye with subfoveal choroidal neovascularization (CNV) or juxtafoveal CNV secondary to AMD~* Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 65 to 10 in the study eye~* Willing and able to comply with clinic visits and study-related procedures~* Provide signed inform consent~Exclusion Criteria:~* Macular edema or CMV secondary to any causes other than AMD in the study eye~* Previously-treated patients who are not responders to anti-VEGF~* Any condition that may preclude improvement in visual acuity in the study eye~* Previous vitreoretinal surgery, filtration surgery, and cataract surgery within 3 months in the study eye~Note: Other inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: EXPERIMENTAL): AXT107 0.1 mg/eye
- Mid Dose (Type: EXPERIMENTAL): AXT107 0.25 mg/eye
- High Dose (Type: EXPERIMENTAL): AXT107 0.5 mg/eye

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18 - 80 years of age,~* a single enhancing lesion of the brain with MRI appearance consistent with GBM~* Pathologic confirmation of GBM~* Zubrod Performance Scale (ZPS) \< 2~* Must be able to undergo MRI imaging with gadolinium~* Must have access to a computer and the internet (to use KetoCalculator© on-line Database)~Exclusion Criteria:~* unable to undergo MRI with gadolinium~* genetic disorders of fat metabolism~* patients receiving sodium valproate (may cause false ketone reading in urine)~* diabetes~* enrolled in another treatment trial for GBM

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ketogenic Diet (Type: EXPERIMENTAL): Subjects will adhere to a ketogenic diet prior to the start of and through radiation therapy course until the time of first scan after radiation ends. During radiation course, patients also take temozolomide daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility